港股異動 | 中芯國際升超9%,科創板將於7月7日正式申購
uSMART友信智投7月6日消息,週一港股,中芯國際延續近期強勢走勢,截至10:11分,中芯國際最高觸及36.6港元,升幅10%,市值突破2000億港元,年初至今累升203%。
相關衍生品方面,中芯法興零乙牛C.C(52551.HK)升45.45%,中芯中銀--購A.C(15503.HK)升31.67%。


根據安排,中芯國際本次科創板IPO確定發行價為27.46 元/股,將於7月7日(週二)正式申購。
據統計,如按照募資金額計算,這將是科創板史上最大規模IPO,同時也是A股最近10年來最大規模IPO。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.